Alto Neuroscience, Inc.
ANRO
$27.04
$1.746.88%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.35% | -4.02% | 24.77% | 72.93% | 120.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.34% | -3.27% | 4.62% | 29.57% | 55.35% |
| Operating Income | -11.34% | 3.27% | -4.62% | -29.57% | -55.35% |
| Income Before Tax | -17.60% | -2.94% | -8.37% | -30.23% | -48.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.60% | -2.94% | -8.37% | -30.23% | -48.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.60% | -2.94% | -8.37% | -30.23% | -48.88% |
| EBIT | -11.34% | 3.27% | -4.62% | -29.57% | -55.35% |
| EBITDA | -11.29% | 3.53% | -4.29% | -29.32% | -55.40% |
| EPS Basic | -4.33% | 13.22% | 53.45% | 64.49% | 72.42% |
| Normalized Basic EPS | -5.46% | 14.20% | 53.96% | 64.87% | 72.72% |
| EPS Diluted | -4.33% | 13.22% | 53.45% | 64.49% | 72.42% |
| Normalized Diluted EPS | -5.46% | 14.20% | 53.96% | 64.87% | 72.72% |
| Average Basic Shares Outstanding | 12.59% | 17.47% | 43.53% | 107.30% | 273.54% |
| Average Diluted Shares Outstanding | 12.59% | 17.47% | 43.53% | 107.30% | 273.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |